Talazoparib with enzalutamide

DRUG2 trials

Conditions

Prostate Cancer (Adenocarcinoma)mCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)

Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

RecruitingNCT06844383

Prostate Cancer Clinical Trials ConsortiummCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer (Adenocarcinoma)

Start: 2026-05-04End: 2030-03-01Target: 126Updated: 2026-08-21

Phase 3

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Active, not recruitingNCT03395197

PfizermCRPC

Start: 2017-12-18End: 2027-06-30Updated: 2026-09-08

Future Oncology2026-06-09

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

2026-06-04

TALENT: A randomized phase 2 study of talazoparib with or without enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) alterations after progression on abiraterone acetate.

Journal of Clinical Oncology2026-05-28

Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: Extended follow-up.

Journal of Clinical Oncology2026-05-27

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

2025-11-24

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

2025-07-1613 citations

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

2025-07-164 citations

Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2.

Journal of Clinical Oncology2025-05-281 citations

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.

Journal of Clinical Oncology2025-05-28

Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.

Journal of Clinical Oncology2025-05-28

Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.

Journal of Clinical Oncology2025-05-28

Abstract LB089: Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO-2

Cancer Research2025-04-25

Abstract CT102: Exploring the tumor molecular landscape associated with<i>TMPRSS2-ERG</i>: A post hoc analysis from the phase 3 TALAPRO-2 study of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in metastatic castration-resistant prostate cancer (mCRPC)

Cancer Research2025-04-25

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

2025-04-015 citations

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

2025-04-014 citations

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

2025-03-014 citations

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Journal of Clinical Oncology2025-02-1022 citations

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

Journal of Clinical Oncology2025-02-108 citations

PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

2025-01-145 citations

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: <scp>TALAPRO</scp> ‐2 Japanese Subgroup Analysis

Cancer Medicine2024-12-311 citations

34 more papers not shown

Talazoparib with enzalutamide

Sponsors

Conditions

Phase 2

Phase 3

Related Papers